Get the Stockscreener App
1.38
0.00%
0.00
Renovorx Inc stock is traded at $1.38, with a volume of 162.69K.
It is up +0.00% in the last 24 hours and up +13.11% over the past month.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
See More
Previous Close:
$1.38
Open:
$1.36
24h Volume:
162.69K
Relative Volume:
1.11
Market Cap:
$49.74M
Revenue:
-
Net Income/Loss:
$-9.16M
P/E Ratio:
-2.4211
EPS:
-0.57
Net Cash Flow:
$-8.75M
1W Performance:
+6.15%
1M Performance:
+13.11%
6M Performance:
+10.40%
1Y Performance:
+6.15%
1-Day Range:
$1.31
$1.39
1-Week Range:
$1.31
$1.40
52-Week Range:
$0.75
$1.6899
Renovorx Inc Stock (RNXT) Company Profile
Name
Renovorx Inc
Sector
Industry
Phone
408-800-2649
Address
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
1.38 | 49.74M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
509.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
309.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
247.08 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Renovorx Inc Stock (RNXT) Latest News
Short Interest in RenovoRx, Inc. (NASDAQ:RNXT) Declines By 35.4% - Defense World
Citadel Advisors LLC Invests $49,000 in RenovoRx, Inc. (NASDAQ:RNXT) - Defense World
RenovoRX chief medical officer buys $29,399 in common stock By Investing.com - Investing.com Canada
RenovoRX chief medical officer buys $29,399 in common stock - Investing.com Australia
Insider Buying: Ramtin Agah Acquires Additional Shares of RenovoRx Inc (RNXT) - GuruFocus
RenovoRx (NASDAQ:RNXT) Stock Rating Upgraded by Wall Street Zen - Defense World
RenovoRx (NASDAQ:RNXT) Given New $11.50 Price Target at Ascendiant Capital Markets - Defense World
RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results - Yahoo Finance
Ascendiant Capital raises RenovoRx stock price target to $11.50 By Investing.com - Investing.com Canada
RenovoRx (RNXT) Price Target Increased by Ascendiant Analyst | R - GuruFocus
RenovoRx (RNXT) Price Target Increased by Ascendiant Analyst | RNXT Stock News - GuruFocus
RenovoRx (RNXT) Price Target Raised to $11.50 by Ascendiant Capi - GuruFocus
Ascendiant Capital raises RenovoRx stock price target to $11.50 - Investing.com
New U.S. Patent Issued to RenovoRx for Drug Therapy Platform - Medical Product Outsourcing
RenovoRx (NASDAQ:RNXT) Is Revolutionizing Cancer Treatment - simplywall.st
Q2 Earnings Forecast for RenovoRx Issued By HC Wainwright - Defense World
RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates - MSN
RenovoRx (NASDAQ:RNXT) Receives “Buy” Rating from HC Wainwright - Defense World
RenovoRx Buy Rating: Promising RenovoCath Adoption and TIGeR-PaC Study Progress Drive Positive Outlook - TipRanks
RenovoRx (RNXT): HC Wainwright Reiterates Buy Rating with $3.00 Target | RNXT Stock News - GuruFocus
RenovoRx, Inc. (NASDAQ:RNXT) Q1 2025 Earnings Call Transcript - MSN
RenovoRx’s Innovative Drug Delivery and Promising Clinical Trials Earn a Buy Rating - TipRanks
RenovoRx Earnings Call: Positive Outlook Amid Growth - TipRanks
RenovoRx Inc (RNXT) Q1 2025 Earnings: EPS of -$0.08 Beats Estima - GuruFocus
RenovoRx earnings beat, revenue fell short of estimates - Investing.com Australia
Earnings call transcript: RenovoRx Q1 2025 revenue exceeds expectations By Investing.com - Investing.com Nigeria
RenovoRx Reports Promising Q1 2025 Financial Results - TipRanks
Earnings call transcript: RenovoRx Q1 2025 revenue exceeds expectations - Investing.com
RenovoRx earnings beat, revenue fell short of estimates By Investing.com - Investing.com India
RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights - BioSpace
RenovoRx Q1 2025 Earnings Call Transcript - MarketBeat
RenovoRx reports Q1 EPS (8c), consensus (8c) - TipRanks
RenovoRx (RNXT) Reports Strong Q1 Revenue Surpassing Expectations | RNXT Stock News - GuruFocus
RenovoRx Reports Strong Q1 2025 Financial Results - TipRanks
RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st - BioSpace
RenovoRx Expands RenovoCath Production to Meet an Increasing Demand - Zenopa
Renaissance Technologies LLC Makes New Investment in RenovoRx, Inc. (NASDAQ:RNXT) - Defense World
RenovoRx Ramps Up U.S. Production of RenovoCath Devices - Medical Product Outsourcing
U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform - Business Wire
RenovoRx (RNXT) Projected to Post Earnings on Friday - Defense World
RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET - BioSpace
CM24 Combo With Biomarker Targeting Improves Survival in Pancreatic Cancer - Curetoday
Ascendiant Capital Markets Forecasts Strong Price Appreciation for RenovoRx (NASDAQ:RNXT) Stock - The AM Reporter
RenovoRx (RNXT) Advances Phase III Trial for Pancreatic Cancer T - GuruFocus
RenovoRx (RNXT) Advances Phase III Trial for Pancreatic Cancer Treatment | RNXT Stock News - GuruFocus
Johns Hopkins Medicine Initiates Patient Enrollment For Renovorx'S Ongoing Phase III Tiger-Pac Clinical Trial - marketscreener.com
Renovorx Inc Stock (RNXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Renovorx Inc Stock (RNXT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Marton Laurence | Director |
May 02 '25 |
Option Exercise |
0.15 |
20,480 |
3,072 |
66,164 |
| Agah Ramtin | Chief Medical Officer |
Apr 15 '25 |
Buy |
0.90 |
15,000 |
13,500 |
1,113,460 |
| Bagai Shaun | Chief Executive Officer |
Apr 15 '25 |
Buy |
0.91 |
7,500 |
6,821 |
320,040 |
| Agah Ramtin | Chief Medical Officer |
Apr 11 '25 |
Buy |
0.80 |
20,000 |
16,000 |
1,098,460 |
| Kocak Ron | VP Controller and PAO |
Apr 10 '25 |
Buy |
0.79 |
6,500 |
5,135 |
12,595 |
| Kocak Ron | VP Controller and PAO |
Apr 09 '25 |
Buy |
0.80 |
6,000 |
4,800 |
6,095 |
| Kocak Ron | VP Controller and PAO |
Apr 08 '25 |
Buy |
0.80 |
95 |
76 |
95 |
| Agah Ramtin | Chief Medical Officer |
Apr 09 '25 |
Buy |
0.81 |
30,000 |
24,399 |
1,078,460 |
| Bagai Shaun | Chief Executive Officer |
Apr 09 '25 |
Buy |
0.83 |
10,000 |
8,300 |
312,540 |
| Marton Laurence | Director |
Apr 08 '25 |
Buy |
0.85 |
12,050 |
10,218 |
45,684 |
1.86%
1.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):